The Molecular Basis of DMD and Why It Is Difficult to Treat
Duchenne Muscular Dystrophy is an X-linked recessive disorder caused by frameshift mutations in the dystrophin gene — a 2.2 megabase, 79-exon locus on the X chromosome that encodes a 427 kDa structural protein essential for linking the intracellular cytoskeleton to the extracellular matrix via the dystrophin-associated glycoprotein complex (DGC). When these mutations prevent production of functional full-length dystrophin, the result is membrane fragility, calcium influx, proteolytic cascades, and progressive fiber necrosis and fibrosis affecting approximately 1 in 3,500–6,000 live male births.
The therapeutic challenge is compounded by the gene’s extraordinary size. The full-length dystrophin cDNA spans approximately 14 kb — more than three times the standard packaging capacity of adeno-associated virus vectors (~4.7 kb), which are the preferred delivery vehicle for in vivo gene therapy. This single constraint has driven an entire sub-field of microdystrophin engineering, as documented across at least 12 distinct patent filings in the retrieved dataset.
Patent data converge on two principal deletion hotspot regions: exons 42–55 (mid-distal) and exons 3–19 (proximal). Approximately 80% of DMD deletions cluster in the mid-distal hotspot, making exons 44, 45, 50, 51, 52, and 53 the most therapeutically targeted for exon-skipping strategies. Exon 51 skipping alone is applicable to approximately 20% of DMD deletion patients — the broadest single-exon applicability in the dataset — explaining why it was the target of the first FDA-approved ASO, eteplirsen (Exondys 51), developed by Sarepta Therapeutics.
Duchenne Muscular Dystrophy affects approximately 1 in 3,500–6,000 live male births and is caused by frameshift mutations in the dystrophin gene, a 2.2 megabase, 79-exon locus on the X chromosome encoding a 427 kDa structural protein. Approximately 80% of DMD deletions cluster in the mid-distal hotspot region covering exons 42–55.
Secondary molecular targets identified across retrieved patent filings include utrophin (a structural homologue of dystrophin whose upregulation can compensate for dystrophin absence), alpha7beta1 integrin (a compensatory adhesion complex), PDE5A (phosphodiesterase type 5A), and the aryl hydrocarbon receptor (AHR) — each representing a distinct mechanistic entry point for therapeutic intervention, as documented by filings from the University of Pennsylvania, University of Nevada Reno, University of Iowa Research Foundation, and Peptris Technologies, respectively. According to OMIM, the DMD gene was first characterised in 1986 and remains one of the largest known human genes.
Antisense Oligonucleotides: From PMOs to Conjugate Delivery
Antisense oligonucleotides for exon skipping represent the largest single cluster in the retrieved patent dataset — at least 20 distinct filings — and the modality with the most commercially validated precedent. The therapeutic rationale is to convert a severe DMD phenotype into a milder Becker muscular dystrophy-like state by enabling production of a truncated but partially functional dystrophin protein.
PMOs employ an uncharged phosphorodiamidate backbone and six-membered morpholino ring, conferring nuclease resistance and reduced off-target protein binding compared to earlier phosphorothioate chemistries. Both eteplirsen (exon 51) and golodirsen (exon 53) — the two FDA-approved Sarepta Therapeutics ASOs referenced in the patent dataset — are PMO-class drugs.
Phosphorodiamidate morpholino oligomers dominate the chemistry landscape in retrieved filings. Beyond standard PMOs, the dataset documents a spectrum of chemical innovations: ENA (2′-O,4′-C-ethylene-bridged nucleic acid) chemistry from Orphan Disease Treatment Institute targeting dystrophin cDNA sequences 2571–2607; tricyclo-DNA (tc-DNA) antisense oligonucleotides from the University of Bern (2012) and Association Institut de Myologie (2019) with claimed systemic CNS penetration; 2′-O-methyl phosphorothioate oligonucleotides underlying drisapersen (exon 51, BioMarin Technologies B.V.), though retrieved data note this candidate showed insufficient efficacy and safety concerns; and inosine-containing oligonucleotides for wobble base-pair formation, also from BioMarin Technologies B.V. Wave Life Sciences (2024) filed on stereocontrolled oligonucleotide compositions claiming improved pharmacological properties through defined stereochemistry at phosphorus centers.
Antibody-Oligonucleotide Conjugates: The Fastest-Moving IP Cluster
The most active emerging IP cluster in the retrieved dataset is antibody-oligonucleotide conjugates (AOCs), in which anti-transferrin receptor 1 (TfR1) antibodies or antigen-binding fragments are conjugated to PMO molecules. The anti-TfR1 moiety enables receptor-mediated internalization into muscle cells, potentially overcoming the key limitation of unconjugated PMOs: poor tissue penetration and intracellular delivery. Avidity Biosciences has filed across exon targets 44, 50, and 52 in a compressed 2023–2025 window across WO, US, CN, TW, and CA jurisdictions, with drug-to-antibody ratios (DARs) of approximately 4 and 8 described for these PMO conjugates.
Dyne Therapeutics (2024–2026) similarly discloses muscle-targeting complexes using anti-TfR1 Fab fragments conjugated to ASOs, with functional outcome data in mdx mouse models including wheel running distance and hindlimb fatigue challenge measurements. Entrada Therapeutics filed a cyclic peptide-ASO conjugate targeting exon 44, using a macrocyclic cell-penetrating peptide to improve intramuscular delivery. These filings collectively signal that delivery technology — not ASO sequence design — has become the primary IP battleground in the exon-skipping space, as documented by WIPO patent records.
“Delivery technology — not ASO sequence design — has become the primary IP battleground. Avidity Biosciences filed across exon targets 44, 50, and 52 in a compressed 2023–2025 window across five jurisdictions.”
Track DMD patent filings across ASO chemistries, AOC platforms, and gene therapy assignees in real time.
Explore DMD Patent Data in PatSnap Eureka →Antisense oligonucleotides for DMD exon skipping represent the largest single cluster in the patent dataset, with at least 20 distinct filings. Phosphorodiamidate morpholino oligomers (PMOs) dominate the chemistry landscape. Eteplirsen (exon 51) and golodirsen (exon 53) — both PMO-class drugs from Sarepta Therapeutics — received FDA accelerated approval in 2016 and subsequently, respectively, and are the most cited approved agents in the retrieved filings.
AAV Microdystrophin Gene Therapy: A Crowded and Geographically Distributed IP Landscape
AAV-mediated microdystrophin gene therapy constitutes the second largest modality cluster in the retrieved dataset, with at least 12 distinct patent filings from at least six distinct assignees. The central engineering challenge — that the full-length dystrophin cDNA (~14 kb) exceeds standard AAV packaging capacity (~4.7 kb) — has driven the development of truncated constructs that retain critical functional domains (N-terminal actin-binding domain, cysteine-rich domain, selected spectrin-like repeats and hinges) while omitting dispensable central rod domain repeats.
AAV serotypes 8 and 9 are the predominant vectors described across retrieved filings. REGENXBIO data demonstrate sarcolemmal microdystrophin localization and functional improvement in mdx mice at doses of 1×10¹⁴ GC/kg or greater. The Research Institute at Nationwide Children’s Hospital has filed extensively on muscle-specific micro-dystrophin AAV vectors with muscle creatine kinase (MCK) promoters for skeletal, diaphragm, and cardiac muscle expression, including a co-treatment step of immune system suppression alongside rAAV administration — a clinically relevant translational consideration reflecting known anti-capsid immune response risks.
Safety de-targeting is an emerging differentiation axis. Kate Therapeutics (2025) filed an AAV composition incorporating miRNA de-targeting sequences — specifically miR-338-3p, miR-138-5p, and miR-9-5p — to suppress dorsal root ganglion expression, addressing a known safety concern for AAV gene therapies. Sarepta Therapeutics filed a recombinant AAV patent describing genotyping of the subject’s DMD gene to determine whether rAAV gene therapy is contraindicated, signalling awareness of immune response risk in clinical translation. These safety-focused filings are consistent with guidance from regulatory bodies including the FDA on AAV gene therapy development.
The University of Washington has filed on a dual and triple AAV vector co-delivery strategy (“SIMPLI-GT”) for expressing large proteins — including full-length or near-full-length dystrophin — by split-intein reconstitution. This approach directly addresses the fundamental size limitation of single-vector microdystrophin strategies and represents a qualitative shift in therapeutic ambition. CRISPR Therapeutics and Vertex Pharmaceuticals hold separate DMD CRISPR filings describing SaCas9-based guide RNA sequences for in vivo genome editing of the dystrophin gene, though retrieved content for these programs is preclinical only.
AAV-mediated microdystrophin gene therapy for Duchenne Muscular Dystrophy is represented by at least 12 distinct patent filings from at least six assignees in the retrieved dataset, including REGENXBIO, Nationwide Children’s Hospital, Sarepta Therapeutics, University of Washington, Kate Therapeutics, and University of North Carolina. AAV serotypes 8 and 9 are the predominant vectors, with REGENXBIO data demonstrating functional improvement in mdx mice at doses of 1×10¹⁴ GC/kg or greater.
Small Molecules and Utrophin Upregulation: Mutation-Independent Strategies
Small molecule approaches for DMD appear in a distinct but smaller cluster of retrieved patent filings, with several mechanistic targets spanning vasodilatory, anti-inflammatory, and compensatory pathways. Their strategic value lies in mutation-independence: unlike exon-skipping ASOs (which are applicable only to patients with specific deletion genotypes) or gene therapy constructs (which face manufacturing and immune challenges), small molecules targeting utrophin upregulation or inflammatory signalling are theoretically applicable to all DMD patients regardless of their specific dystrophin mutation.
Peptris Technologies Private Limited (WO, 2025) describes atovaquone — an approved antiparasitic drug — as a repurposed agent capable of inhibiting the aryl hydrocarbon receptor (AHR) to upregulate utrophin in DMD muscles. This represents one of the most recently filed small molecule signals in the dataset and suggests a potential near-term clinical path via drug repurposing, bypassing early-phase safety studies.
PDE5A inhibitors are documented in two filings: University of Iowa Research Foundation (US, 2011) and Kevin P. Campbell (WO, 2010), with rationale centered on improving blood flow to ischemic dystrophic muscle and modulating cGMP/NF-κB/heme oxygenase-1 pathways. Zebrafish and mdx mouse models are referenced. HDAC inhibitors — specifically Trichostatin A and AR-42 — are described in a University of Pennsylvania filing (US, 2023) as post-transcriptional utrophin upregulators. Summit Corporation PLC (ES, 2014) filed compounds of a defined heterocyclic formula for DMD therapy consistent with utrophin upregulation approaches. A University of Campinas academic paper (2017) proposes PKC Theta inhibition as a novel target, citing its role in muscle inflammation and degeneration. Vasoactive intestinal peptide (VIP) analogs are described in a Pharis Biopharmaceuticals filing (2017) on elastin-like peptide-stabilized VIP therapeutics for reducing fibrosis and improving muscle function in mdx mouse models.
Despite the variety of mechanisms represented, none of the small molecule approaches in the retrieved dataset are described with clinical data. Research published in Nature journals has highlighted utrophin upregulation as a compelling compensatory strategy, and the atovaquone filing from Peptris Technologies suggests renewed commercial interest in this pathway as of 2025.
Identify emerging small molecule targets and repurposing opportunities across the full DMD patent landscape.
Analyse DMD Drug Targets in PatSnap Eureka →Combination Approaches and Next-Generation Directions
Retrieved patent filings signal several combination and next-generation strategies that extend beyond single-modality intervention, reflecting increasing sophistication in the translational ambitions of DMD drug developers.
AAV + Antifibrotic Co-Expression
The Nationwide Children’s Hospital filing describes co-delivery of miR-29c alongside microdystrophin via a single rAAV construct, with data showing additive benefits in force restoration and fibrosis prevention in mdx/utrophin+/- mice — described as a particularly aggressive disease model. This combination addresses two distinct pathological processes (dystrophin absence and fibrotic remodelling) with a single vector, a clinically meaningful efficiency gain.
ASO + Anti-Inflammatory Adjuncts
BioMarin Technologies B.V. (IL filings, 2021–2022) explicitly describes combining exon-skipping ASOs with anti-inflammatory compounds including antioxidants and IGF-1 analogs, or compounds improving muscle fiber integrity and survival. Retrieved data note that oxidative stress and peroxidized lipids are elevated in DMD patients, supporting the mechanistic rationale for antioxidant combination therapy alongside exon skipping.
CRISPR + AAV for Permanent Genomic Correction
Vertex Pharmaceuticals (CN, 2023) describes a single AAV construct encoding both SaCas9 and multiple guide RNAs targeting DMD exons, enabling permanent genomic correction rather than transient exon skipping. This represents a qualitative shift in therapeutic ambition — from reading frame restoration on a transcript-by-transcript basis to permanent genomic rewriting. Retrieved content for these programs is preclinical only, and the approach faces immune, off-target, and manufacturing challenges not addressed in retrieved filings. The NIH has funded multiple preclinical CRISPR programs for DMD, reflecting the long-duration translational horizon of this modality.
Dual/Triple AAV for Full-Length Dystrophin
University of Washington filings (CN, 2024) describe split-intein-mediated protein reconstitution using two or three AAV vectors to express near-full-length or full-length dystrophin — directly addressing the fundamental size limitation of single-vector microdystrophin approaches. This strategy, if clinically validated, would represent a significant advance over current microdystrophin constructs that necessarily omit functional rod domain repeats.
Combination strategies in the DMD patent dataset include AAV microdystrophin co-expressed with miR-29c for antifibrotic benefit (Nationwide Children’s Hospital), ASOs combined with anti-inflammatory adjuncts including antioxidants and IGF-1 analogs (BioMarin Technologies B.V.), and single AAV constructs encoding both SaCas9 and multiple guide RNAs for permanent genomic correction (Vertex Pharmaceuticals, 2023). All combination approaches described in retrieved filings are at preclinical stage.
Strategic Implications for IP and R&D Teams
The DMD patent landscape reveals a field in transition: commercially validated ASO IP is maturing and fractionating, while delivery innovation and gene-level correction are driving the next wave of competitive differentiation. Several strategic implications emerge directly from the retrieved dataset.
Exon-Targeting ASO IP Is Maturing
Sarepta Therapeutics holds broad PMO IP for the commercially validated exon 51 and 53 positions. Competitive differentiation is now being sought at earlier-stage exons (44, 50, 52) and through delivery innovations — AOCs, CPP-PMOs, cyclic peptide conjugates — making delivery technology the primary IP battleground. Sarepta’s CN filing (2023) describes a novel dosing regimen combining cell-penetrating peptide (CPP)-conjugated PMOs with magnesium supplementation, illustrating the granularity of competitive positioning now required.
Anti-TfR1 AOC Platform Is the Most Active Emerging IP Space
Avidity Biosciences has filed across multiple exon targets and jurisdictions within a compressed 2023–2025 window. Dyne Therapeutics is a direct competitor in the muscle-targeting conjugate space, with filings extending to fibrosis inhibition as an emerging secondary indication. First-mover advantage in this modality will likely depend on clinical proof-of-concept for muscle delivery efficiency — data not yet present in the retrieved dataset for either company’s AOC programs.
AAV Gene Therapy IP Is Crowded
At least six distinct assignees hold active or pending AAV microdystrophin patents. Differentiation signals center on capsid serotype, microdystrophin domain composition, immune management co-treatment, and safety de-targeting of dorsal root ganglia. These dimensions will be critical in future regulatory or licensing negotiations. According to EMA guidance on advanced therapy medicinal products, immune management co-treatment is a key regulatory consideration for AAV gene therapies.
Small Molecule Utrophin Upregulation Remains Underdeveloped
Multiple mechanisms for utrophin upregulation are represented in the dataset — HDAC inhibition, AHR inhibition via atovaquone, PDE5A inhibition — but none are described with clinical data. The mutation-independence of this approach gives it strategic value applicable to all DMD genotypes, and the 2025 atovaquone filing from Peptris Technologies suggests a potential near-term clinical path via drug repurposing. IP teams monitoring this space should track whether any of these mechanisms advances to IND-enabling studies. PatSnap’s life science intelligence platform enables monitoring of exactly these translational signals across global patent and literature databases.
“The mutation-independence of utrophin upregulation approaches — applicable to all DMD genotypes — gives them strategic value if clinical translation can be demonstrated. The 2025 atovaquone filing suggests a potential near-term clinical path via repurposing.”
For R&D and IP teams navigating this landscape, the convergence of modalities creates both opportunity and complexity. Monitoring patent filings across ASO chemistry, AOC platforms, AAV capsid engineering, and small molecule repurposing simultaneously requires systematic intelligence infrastructure. PatSnap Eureka’s drug discovery intelligence tools are designed to surface exactly these cross-modality signals from global patent and literature databases.